C18 Dihydroceramide
- Product Name
- C18 Dihydroceramide
- CAS No.
- 2304-80-5
- Chemical Name
- C18 Dihydroceramide
- Synonyms
- C18 Dihydroceramide (d18:0/18:0);C18 Dihydroceramide (d18:0/18:0)/Ceramide NG;N-[(2S,3R)-1,3-Dihydroxy-2-octadecyl]stearamide;N-[(1S,2R)-2-Hydroxy-1-(hydroxyMethyl)heptadecyl]octadecanaMide;N-STEAROYL-D-ERYTHRO-SPHINGANINE;C18 DIHYDROCERAMIDE (D18:0/18:0);Octadecanamide, N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-
- CBNumber
- CB81176179
- Molecular Formula
- C36H73NO3
- Formula Weight
- 567.97
- MOL File
- 2304-80-5.mol
C18 Dihydroceramide Property
- Melting point:
- 104-106°C
- Boiling point:
- 694.8±45.0 °C(Predicted)
- Density
- 0.909±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: Soluble; Ethanol: Warmed
- form
- A crystalline solid
- pka
- 14.30±0.20(Predicted)
N-Bromosuccinimide Price
- Product number
- 24379
- Product name
- C18 dihydro Ceramide (d18:0/18:0)
- Packaging
- 5mg
- Price
- $93
- Updated
- 2024/03/01
- Product number
- 24379
- Product name
- C18 dihydro Ceramide (d18:0/18:0)
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $176
- Updated
- 2024/03/01
- Product number
- 24379
- Product name
- C18 dihydro Ceramide (d18:0/18:0)
- Packaging
- 25mg
- Price
- $343
- Updated
- 2024/03/01
- Product number
- C263060
- Product name
- C18Dihydroceramide
- Packaging
- 1mg
- Price
- $160
- Updated
- 2021/12/16
- Product number
- 8750CN
- Product name
- N-(Octadecanoyl)-sphinganine
- Packaging
- 5mg
- Price
- $201
- Updated
- 2021/12/16
C18 Dihydroceramide Chemical Properties,Usage,Production
Chemical Properties
White Crystalline Solid
Uses
C18 Dihydroceramide can be used for ceramide composition with repairing function and cosmetic.
Definition
ChEBI: N-octodecanoylsphinganine is a dihydroceramide in which the ceramide N-acyl group is specified as octadecanoyl (stearoyl). It has a role as a mouse metabolite. It is a N-acylsphinganine and a N-stearoyl-sphingoid base. It is functionally related to an octadecanoic acid.
Biological Activity
Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway. vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients. Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection.